… Whether or not molnupiravir will prove effective in treating COVID-19 will be determined
in … of potent antiviral agents in the COVID-19 pipeline strongly argues for such accelerated …

… high risk of severe COVID-19 treated with molnupiravir. Methods: … , COVID-19 symptoms
with the onset of up to 5 days, and at high risk of severe COVID-19 illness received molnupiravir …

… Nevertheless, our findings support the use of molnupiravir and nirmatrelvir for treating …
studies to evaluate the combination of molnupiravir and nirmatrelvir for treating COVID-19. …

… explained why molnupiravir failed for the treatment of COVID-19 in … that molnupiravir was
most effective at combatting COVID-19 … Currently available COVID-19 vaccines are unable to …

… molnupiravir), (iii) summarizes the clinical progress of other oral antivirals for use in COVID-19…
Oral COVID-19 antivirals represent a part of the strategy to adapt to long-term co-existence …

… any treatment that has received full FDA approval for COVID-19. Numerous agents have
been approved under EUA for the treatment … use under EUA for the treatment of mild-moderate …

… is found to be the first orally acting efficacious drug to treat COVID-19 cases. It was … treating
adults with mild to moderate COVID-19 patients. Considering the importance of molnupiravir, …

… In the ferret model of influenza, treatment of pandemic influenza A virus with molnupiravir …
diseases, including COVID-19. The ability of molnupiravir to potentially treat highly pathogenic …

… with molnupiravir in humans to treat COVID-19 [2]. Initially, molnupiravir was developed for
the treatment … Nowadays, coronavirus is one of the most discussed and actively investigated …

… VOC delta was excluded from transmission studies, since we had not detected any infectious
particles in nasal lavages of molnupiravir-treated animals at any time and nasal turbinates …